4 / 11
Page 15
Notes:
allied
academies
Journal of Medical Oncology & Therapeutics | Volume 4
March 18-19, 2019 | London, UK
Oncology & Cancer Therapy
International Conference on
T
he idea of using the immune system to fight cancer is
over 100 years old. (Paul Ehrlich’s “Magic Bullet”). A new
molecular approach led to a better understanding of the
immune system. Check point regulation, understanding roles
of Tregs, Th1 and Th2, development of CAR-T cells, as well as
regulation of DC and Macrophages, has led to discovery of
immune checkpoint inhibitors (ICI) and modulators that are
currently used in studies of several STs. Positive studies have
led to the US FDA approval of a number of these compounds
but none to date are approved in breast cancer (BrCa).
Moreover, PD-1 / PDL-1, MSI high (and dMMR), MTB are
the currently “best” predictive markers for IO therapy. BrCa
actually has some of these markers positive only in subsets
and less frequently expressed than most other tumors e.g.
malignant melanoma or non-small cell lung cancer and
others. In order to improve the potential efficacy of ICI in
breast cancer, the addition of chemotherapy was one of the
strategies. Many early and large clinical trials in all phases,
are underway in BrCa and will be reported in 2018 and 2019.
We will discuss the mechanism of action, its impact on BrCa
and some of the early results and next generations ICI.
Speaker Biography
Stefan Glueck is the Vice President, Global Medical Affairs, at Celgene Corporation
since October 2014, and a medical oncologist with focus on breast cancer. He has
overseen oncology activities worldwide, as well as the Immuno-Oncology Program in
solid tumors and hematology. Recently, his job requirements have shifted to include
Early Assets. He was presented the “America’s Top Oncologists” 2008 award from
Consumers’ Research Council of America, as well as “Best Doctors in America” honor
since 2006 and has annually earned that prestige every year to 2014. This award was
warranted after less than 3 years of working in the United States. He is a member
of such prestigious professional organizations, as the American Society of Clinical
Oncology, European Society for Medical Oncology, American & European Association
of Cancer Research, and the International Association for Breast Cancer Research. He
has authored or co-authored over 270 articles. In addition, he has written or co-written
several book chapters and numerous journal abstracts and has presented more than
380 papers at national and international meetings.
e:
sgluck@celgene.comStefan Glueck
Celgene Corporation, USA
Finally we have positive data in the treatment of breast cancer using ICI